Automating Purchasing Helps FUJIFILM Diosynth Biotechnologies Focus on Its True Mission

separator

In the field of biotechnology commercialization, delays in purchasing can delay getting treatments to patients who can benefit from the latest therapeutic advancements. FUJIFILM Diosynth Biotechnologies understands the need to get to market quickly and cost effectively to improve the quality of life for people across the globe. The latest step that they have taken to support this mission is to implement leading source-to-pay solutions that will help them automate the organization’s purchasing processes.

The procurement team for this leading global biologics Contract Development and Manufacturing Organization (CDMO) projects that the new JAGGAER software package, including Spend Director, Accounts Payable Director and Spend Radar, will achieve substantial financial savings and provide greater visibility into the purchasing process for all stakeholders.

“Our primary goal with the rollout of the new JAGGAER solution is to automate as much of the purchasing process as possible,” said Neal Falcone, Senior Procurement Manager, FUJIFILM Diosynth Biotechnologies U.S.A., Inc. “By simplifying the requisition process, we are allowing our employees to focus on more strategic activities, while also reducing processing times for the business. It’s a win-win.”

The JAGGAER cloud-based solution will integrate seamlessly with FDBU’s existing SAP ERP system. Integrating JAGGAER’s source-to-pay software with the company’s core financial system will drive more detailed and accurate cost accounting and enhance visibility into overall spend through improved data capture.

“Fujifilm Diosynth Biotechnologies is the latest global company to adopt our comprehensive source-to-pay solutions. Our technology is being adopted as the best-in-class spend solutions suite within the commercial space,” says Robert Bonavito, CEO of JAGGAER.

Please follow and like us:
LinkedIn
Google+
Google+
https://www.jaggaer.com/automating-purchasing-helps-fujifilm-diosynth-biotechnologies-focus-true-mission/